The AHA Scientific Sessions featured a range of presentations on the PCSK9 inhibitors including final study data from ORION-9 and ORION-10 showing the effectiveness of twice-yearly inclisiran in patients with heterozygous familial hypercholesterolaemia and atherosclerotic cardiovascular disease. New analyses from FOURIER highlighted the impact of evolocumab on every day cognition and in patients who had experienced a recent myocardial infarction. Abstracts presented during the congress also included new patient-centred outcomes data from ODYSSEY OUTCOMES in patients with acute coronary syndrome and in older patients. In addition, there was a presentation on an open label phase 2B trial on LIB003.

Read these reports and others here:

• ORION-9: durable and potent LDL-C lowering in HeFH patients on twice-yearly dosing
• ORION-10: effective LDL-C lowering in patients with ASCVD with twice yearly dosing
• FOURIER: effects of evolocumab on cognition and following MI
• ODYSSEY OUTCOMES: alirocumab reduces total hospitalisations, increases DAOH
• Alirocumab shows benefit post-MI
• LIB003: open label extension phase 2B study shows promise
• ODYSSEY OUTCOMES: alirocumab benefits in older patients

View the reports from AHA 19 here »

Education: the primary mission of PCSK9 Forum.

Don’t forget to check back for the latest updates to the PCSK9 Forum educational slide resource programme